Sawai Group Holdings Co., Ltd.

4887

JP3323040000

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:00:00 28/06/2024 BST			5-day change	1st Jan Change
6,537 ^JPY	+2.48%		+14.08%	+25.49%

06-26	Sawai Group Plans 33 Billion Yen Share Buyback; Shares Up 8%	MT
06-25	Sawai Group Holdings Co., Ltd. announces an Equity Buyback for 6,900,000 shares, representing 15.75% for ¥33,000 million.	CI

Sawai Group Holdings Co., Ltd. authorizes a Buyback Plan.

June 24, 2024

The Board of Directors of Sawai Group Holdings Co., Ltd. has authorized a buyback plan on June 25, 2024.

Latest news about Sawai Group Holdings Co., Ltd.

Sawai Group Plans 33 Billion Yen Share Buyback; Shares Up 8%	06-26	MT
Sawai Group Holdings Co., Ltd. announces an Equity Buyback for 6,900,000 shares, representing 15.75% for ¥33,000 million.	06-25	CI
Sawai Group Holdings Co., Ltd. authorizes a Buyback Plan.	06-24	CI
Transcript : Sawai Group Holdings Co., Ltd. - Special Call	06-05
Transcript : Sawai Group Holdings Co., Ltd., 2024 Earnings Call, May 14, 2024	05-14
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending September 2024 and Fiscal Year Ending March 2025	05-13	CI
Sawai Group Holdings Co., Ltd. Announces Dividend Guidance for the Second Quarter and Fiscal Year Ending March 31, 2025	05-13	CI
Sawai Group Holdings Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 26, 2024	05-13	CI
Sawai Group Finalizes Sale of US Subsidiary	04-03	MT
Bora Pharmaceuticals Co., LTD. completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd..	03-31	CI
Jefferies Adjusts Sawai Group’s Price Target to 5,000 Yen From 5,200 Yen, Keeps at Hold	03-06	MT
Sawai Group Holdings Co., Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2024	02-14	CI
Sawai Group Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	02-14	CI
Bora Pharmaceuticals Co., LTD. agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. for approximately $210 million.	01-15	CI
Neurolief Ltd. announced that it has received funding from Sawai Group Holdings Co., Ltd.	12-27	CI
Jefferies Adjusts Sawai’s Price Target to 4,500 Yen From 3,500 Yen, Keeps at Hold	11-22	MT
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	11-10	CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	11-10	CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024	09/08/23	CI
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for Period Ending September 2023 and Year Ending March 2024	09/08/23	CI
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024	11/05/23	CI
Sawai Group Holdings Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024	11/05/23	CI
Sawai Group Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	10/05/23	CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023	13/02/23	CI
Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	13/02/23	CI

Chart Sawai Group Holdings Co., Ltd.

Duration

Period

More charts

Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sawai Group Holdings Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6,537 JPY

Average target price

6,928 JPY

Spread / Average Target

+5.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SAWAI GROUP HOLDINGS CO., LTD.	+25.49%	1.78B
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals